Technical Analysis for RUBY - Rubius Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Up |
| See historical RUBY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Feb 15 | Crossed Above 20 DMA | Bullish | 0.00% |
| Feb 15 | Pocket Pivot | Bullish Swing Setup | 0.00% |
| Feb 15 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Feb 15 | BB Squeeze + Upper Band Touch | Range Contraction | 0.00% |
| Feb 15 | Upper Bollinger Band Touch | Strength | 0.00% |
| Feb 14 | Lizard Bullish | Bullish Day Trade Setup | 1.97% |
| Feb 14 | Bollinger Band Squeeze | Range Contraction | 1.97% |
| Feb 14 | Doji - Bullish? | Reversal | 1.97% |
| Feb 14 | BB Squeeze + Lower Band Touch | Range Contraction | 1.97% |
| Feb 14 | Lower Bollinger Band Touch | Weakness | 1.97% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-19
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
Biotechnology Cancer Immunology Autoimmune Diseases Rare Diseases Application Software Autoimmunity Therapies For Cancer Autoimmune Disease Computer Aided Engineering Phenylketonuria Enzyme Replacement Therapies Therapeutic Applications
Biotechnology Cancer Immunology Autoimmune Diseases Rare Diseases Application Software Autoimmunity Therapies For Cancer Autoimmune Disease Computer Aided Engineering Phenylketonuria Enzyme Replacement Therapies Therapeutic Applications
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more RUBY news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 33.01 |
| 52 Week Low | 12.7 |
| Average Volume | 222,406 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 15.6914 |
| 20-Day Moving Average | 13.8845 |
| 10-Day Moving Average | 13.899 |
| Average True Range | 1.0183 |
| ADX | 17.45 |
| +DI | 16.7787 |
| -DI | 19.87 |
| Chandelier Exit (Long, 3 ATRs ) | 11.9651 |
| Chandelier Exit (Short, 3 ATRs ) | 15.7549 |
| Upper Bollinger Band | 14.4013 |
| Lower Bollinger Band | 13.3677 |
| Percent B (%b) | 0.58 |
| BandWidth | 7.444272 |
| MACD Line | -0.5025 |
| MACD Signal Line | -0.6323 |
| MACD Histogram | 0.1298 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.59 | ||||
| Resistance 3 (R3) | 15.58 | 15.03 | 15.32 | ||
| Resistance 2 (R2) | 15.03 | 14.62 | 15.04 | 15.23 | |
| Resistance 1 (R1) | 14.50 | 14.36 | 14.77 | 14.51 | 15.14 |
| Pivot Point | 13.95 | 13.95 | 14.08 | 13.96 | 13.95 |
| Support 1 (S1) | 13.42 | 13.54 | 13.69 | 13.43 | 12.80 |
| Support 2 (S2) | 12.87 | 13.28 | 12.88 | 12.71 | |
| Support 3 (S3) | 12.34 | 12.87 | 12.62 | ||
| Support 4 (S4) | 12.35 |
